PODCAST: The importance of treating the constellation of major depressive disorder symptoms

Listen to Prof. Malcolm Hopwood, the Ramsay Health Care Professor of Psychiatry, University of Melbourne speak to Prof. John Tiller, University of Melbourne and Albert Road Clinic, Melbourne, about the importance of treating the constellation of major depressive disorder symptoms.

QUALIFIERS

P values for comparative studies mentioned in this interview

AtWoRC: Open-label study of patients with MDD treated with vortioxetine. The primary endpoint was the correlation between changes in PDQ-D-20 (Perceived Deficits Questionnaire) and WLQ (Work Limitations Questionnaire) at week 12(p< 0.001). Secondary endpoints included mean change from baseline to week 12 in cognitive measures (DSST, PDQ-D-20), p<0.0001.⁶

The incidence of sexual dysfunction was similar to placebo for Brintellix 5–10 mg. At 15–20 mg, the incidence of sexual dysfunction increases.⁸

The majority of cases of nausea in the MDD Short-Term studies were transient and mild to moderate and did not generally lead to cessation of therapy.⁸

Improvements in SHAPS (p < 0.0001) and MADRS anhedonia factors (p < 0.0001), between baseline and 8 week endpoint in patients with MDD (post-hoc analysis).¹¹

References

Malhi, G.S., et al., Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry, 2015. 49(12): p. 1087-206.
Florea, I., et al., The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain and behavior, 2017. 7(3): p. e00622.
Conradi, H., et al., Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychological medicine, 2011. 41(6): p. 1165-1174.
Lerner, D., et al., Work performance of employees with depression: the impact of work stressors. American Journal of Health Promotion, 2010. 24(3): p. 205-213.
Doran, C.M., The evidence on the costs and impacts on the economy and productivity due to mental ill health: an Evidence Check rapid review brokered by the Sax Institute (www.saxinstitute.org.au) for the Mental Health Commission of NSW. 2013.
Chokka, P., et al., Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD). CNS Spectr, 2019. 24(3): p. 338-347.
McIntyre, R.S., et al., A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol, 2014. 17(10): p. 1557-67.
Therapeutic Goods Administration. Vortioxetine (BRINTELLIX) Product Information; Available from: www.ebs.tga.gov.au.
Wang, G., et al., Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study. Curr Med Res Opin, 2015. 31(4): p. 785-94.
Chokka, P.R., et al., Assessment and management of sexual dysfunction in the context of depression. Ther Adv Psychopharmacol, 2018. 8(1): p. 13-23.
Cao B, et al, The efficacy of vortioxetine on anhedonia in patients with major depressive disorder Fron Psychiatry, 2019;10.
Demmyttenaere K, et al., Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psychiatry, 2001. 62(suppl 22): 30-33.
Francois D et al. Antidepressant-induced sexual side effects: incidence, assessment, clinical implications, and management Psychiatr Ann; 2017; 47(3): 154‐160.

Audio: AU-BRIN-0241. September 2021.

Article: AU-BRIN-0379. January 2022.

The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

Brintellix

Brintellix®

PODCAST: The importance of treating the constellation of major depressive disorder symptoms

References

GO TO

BROUGHT TO YOU BY

LUNDBECK AUSTRALIA PRODUCTS

subscribe newsletter